Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Hong · SciRah

Researcher profile · Semantic Scholar

A. Hong

Share profile

A. Hong — researcher profile on SciRah

h-index: 9
Works: 29
Citations: 245

Most-cited papers

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
S. Freedland, R. Sandin, J. Sah, B. Emir +5 more
2021Cancer Medicine51 citations Open access
Semantic Scholar
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Daniel J. George, K. Ramaswamy, Hong-Bo Yang, Qing Liu +7 more
2024Prostate Cancer and Prostatic Diseases24 citations Open access
Semantic Scholar
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.
D. George, N. Agarwal, Jennifer R. Rider, Benjamin Li +6 more
2021Journal of Clinical Oncology23 citations
Semantic Scholar
Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.
S. Freedland, N. Agarwal, K. Ramaswamy, R. Sandin +6 more
202122 citations
Semantic Scholar
Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer
N. Agarwal, Daniel J. George, Zachary Klaassen, R. Sandin +8 more
2024JAMA Network Open19 citations Open access
Semantic Scholar
Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.
U. Swami, A. Hong, N. El-Chaar, D. Nimke +4 more
2021Journal of Clinical Oncology19 citations
Semantic Scholar
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer
U. Swami, A. Hong, N. El-Chaar, K. Ramaswamy +5 more
2023Journal of Urology16 citations Open access
Semantic Scholar
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment
Stephen J. Freedland, Wei Gao, Angela Lax, Hong-Bo Yang +4 more
2024Prostate Cancer and Prostatic Diseases12 citations Open access
Semantic Scholar
616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
D. George, N. Agarwal, K. Ramaswamy, R. Sandin +6 more
2021Annals of Oncology12 citations Open access
Semantic Scholar
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer
Daniel J. George, N. Agarwal, K. Ramaswamy, Zachary Klaassen +10 more
2024Prostate Cancer and Prostatic Diseases7 citations Open access
Semantic Scholar
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
S. Freedland, A. Hong, N. El-Chaar, S. Murty +4 more
2022Prostate Cancer and Prostatic Diseases7 citations Open access
Semantic Scholar
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.
U. Swami, A. Hong, N. El-Chaar, D. Nimke +4 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
S. Freedland, R. Sandin, S. Tagawa, Z. Klaassen +9 more
2021Annals of Oncology7 citations Open access
Semantic Scholar
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer
Stephen J. Freedland, A. Hong, N. El-Chaar, A. D. De Hoedt +7 more
2025Prostate Cancer and Prostatic Diseases4 citations Open access
Semantic Scholar
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
U. Swami, A. Hong, B. Diessner, Christopher Young +6 more
2024Future Oncology4 citations Open access
Semantic Scholar
Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).
J. Parrish, T. Polascik, A. Hong, N. El-Chaar +7 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients.
Stephen J. Freedland, Marty Chakoian, T. Wells, N. El-Chaar +3 more
2024Clinical Genitourinary Cancer2 citations Open access
Semantic Scholar
1384P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019
D. J. George, R. Sandin, N. Agarwal, S. Tagawa +11 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).
S. Freedland, N. Schultz, Anna D. Coutinho, Rupali M. Fuldeore +4 more
20202 citations
Semantic Scholar
Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?
Daniel J. George, K. Ramaswamy, Hong-Bo Yang, Qing Liu +7 more
2025Future Oncology1 citations Open access
Semantic Scholar
Patient (pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs).
S. Freedland, Marty Chakoian, Edward Wells, N. El-Chaar +3 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.
S. Freedland, A. Hong, N. El-Chaar, A. D. De Hoedt +4 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.
S. Freedland, R. Sandin, J. Sah, B. Emir +5 more
2021Journal of Clinical Oncology1 citations
Semantic Scholar
Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States?
Daniel J. George, N. Agarwal, K. Ramaswamy, Zachary Klaassen +10 more
2025Future Oncology0 citations Open access
Semantic Scholar
PD16-12 REAL-WORLD OUTCOMES AMONG MEN WITH NONMETASTATIC CASTRATION-SENSITIVE BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY WITH SHORT PSA DOUBLING TIME RECEIVING EARLY SECONDARY TREATMENT
S. Freedland, Wei Gao, A. Lax, Hongbo Yang +4 more
2023Journal of Urology0 citations
Semantic Scholar
1827P Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)
D. J. George, K. Ramaswamy, H. Yang, Q. Liu +7 more
2023Annals of Oncology0 citations Open access
Semantic Scholar
1410P Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
S. Gupta, A. Hong, N. El-Chaar, C. Young +5 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapy-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA).
A. Morgans, A. Hong, S. Murty, N. El-Chaar +4 more
2022Journal of Clinical Oncology0 citations
Semantic Scholar
Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).
D. George, S. Tagawa, S. Lechpammer, D. Russell +6 more
20200 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Ramaswamy×25
Invite
K. Ramaswamy — researcher profile on SciRah
S. Freedland×14
Invite
S. Freedland — researcher profile on SciRah
R. Sandin×13
Invite
R. Sandin — researcher profile on SciRah
N. El-Chaar×12
Invite
N. El-Chaar — researcher profile on SciRah

×6

Invite

B. Emir — researcher profile on SciRah

Invite

N. Agarwal — researcher profile on SciRah

Hong-Bo Yang×5

Invite

Hong-Bo Yang — researcher profile on SciRah

Stephen J. Freedland×5

Invite

Stephen J. Freedland — researcher profile on SciRah

Invite

D. George — researcher profile on SciRah

Invite

D. Nimke — researcher profile on SciRah

Invite

S. Tagawa — researcher profile on SciRah

Invite

D. Russell — researcher profile on SciRah